Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$1.27B |
| 2 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$706M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$439M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$413M |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Weyerhaeuser
WY
|
+$431M |
| 2 |
Walt Disney
DIS
|
+$223M |
| 3 |
VXX
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
|
+$213M |
| 4 |
Halliburton
HAL
|
+$211M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$204M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.24% |
| 2 | Financials | 5.68% |
| 3 | Healthcare | 5.62% |
| 4 | Consumer Discretionary | 5.04% |
| 5 | Industrials | 3.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5851
Cue Biopharma
CUE
$110M
| $60K | ﹤0.01% |
221
+178
| +414% | +$51.4K |
|
|
FONR
5852
DELISTED
Fonar
FONR
| $60K | ﹤0.01% |
2,432
+1,982
| +440% | +$51.9K |
|
5853
PUT
Groupon
GRPN
$933M
| $60K | ﹤0.01% |
795
-1,105
| -58% | -$97.2K |
|
|
KF
5854
Korea Fund
KF
$243M
| $60K | ﹤0.01% |
1,638
| – | – |
|
|
MBCN
5855
DELISTED
Middlefield Banc Corp
MBCN
| $60K | ﹤0.01% |
2,514
+2,070
| +466% | +$51.2K |
|
5856
Seres Therapeutics
MCRB
$50.2M
| $60K | ﹤0.01% |
393
+278
| +242% | +$45K |
|
5857
Scholar Rock
SRRK
$6.32B
| $60K | ﹤0.01% |
+2,330
| New | +$42.8K |
|
5858
BlackRock TCP Capital
TCPC
$331M
| $60K | ﹤0.01% |
4,246
-454
| -10% | -$6.64K |
|
5859
Direxion Daily Small Cap Bear 3x ETF
TZA
$206M
| $60K | ﹤0.01% |
+18
| New | +$60.9K |
|
5860
CALL
Vicor
VICR
$9.63B
| $60K | ﹤0.01% |
1,300
+600
| +86% | +$33K |
|
5861
CALL
WEC Energy
WEC
$34.6B
| $60K | ﹤0.01% |
900
-300
| -25% | -$20K |
|
5862
PUT
Wendy's
WEN
$1.39B
| $60K | ﹤0.01% |
3,500
-4,700
| -57% | -$82.1K |
|
|
FTCH
5863
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $60K | ﹤0.01% |
+2,200
| New | +$62.3K |
|
|
RRD
5864
CALL
DELISTED
RR Donnelley & Sons Co.
RRD
| $60K | ﹤0.01% |
11,200
-1,200
| -10% | -$6.46K |
|
|
MDCO
5865
CALL
DELISTED
Medicines Co
MDCO
| $60K | ﹤0.01% |
2,000
-1,400
| -41% | -$52.7K |
|
|
LKM
5866
CALL
DELISTED
Link Motion Inc.
LKM
| $60K | ﹤0.01% |
91,300
-6,100
| -6% | -$6.01K |
|
5867
CALL
Brighthouse Financial
BHF
$3.46B
| $59K | ﹤0.01% |
1,341
| – | – |
|
5868
Immunic
IMUX
$192M
| $59K | ﹤0.01% |
534
+528
| +8,800% | +$1.38M |
|
5869
OP Bancorp
OPBK
$233M
| $59K | ﹤0.01% |
5,048
+4,137
| +454% | +$51.7K |
|
5870
Spyre Therapeutics
SYRE
$9.29B
| $59K | ﹤0.01% |
245
+197
| +410% | +$46K |
|
5871
PUT
ProShares Ultra Gold
UGL
$807M
| $59K | ﹤0.01% |
+7,200
| New | +$61.3K |
|
|
CUTR
5872
PUT
DELISTED
Cutera, Inc.
CUTR
| $59K | ﹤0.01% |
1,800
+800
| +80% | +$29.2K |
|
|
GMLP
5873
PUT
DELISTED
Golar LNG Partners LP
GMLP
| $59K | ﹤0.01% |
4,100
+1,100
| +37% | +$16.1K |
|
|
TNAV
5874
DELISTED
Telenav Inc.
TNAV
| $59K | ﹤0.01% |
11,705
+9,438
| +416% | +$51.8K |
|
|
WUBA
5875
PUT
DELISTED
58.com Inc
WUBA
| $59K | ﹤0.01% |
+800
| New | +$55.3K |
|
Similar funds
Barclays's Q3 2018 Portfolio in Review
As of Q3 2018, Barclays held 7,740 positions worth $144B, up 24% from $116B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Barclays deployed $22.2B of net new capital in Q3 2018, opening 680 new positions and adding to 3,884 existing holdings. Its largest new stake was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
By sector, the portfolio is most concentrated in Technology at 8.2% of assets, up from 7.4% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Weyerhaeuser, an estimated $431M trimmed.
- Barclays's largest Q3 2018 buy was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
- Barclays added most to Fortive in Q3 2018, an estimated $1.27B increase.
- Barclays's biggest Q3 2018 reduction was Weyerhaeuser, cutting an estimated $431M.
- Barclays fully exited Validus Hold Ltd in Q3 2018, selling an estimated $71M.
- Barclays's ten largest holdings make up 31% of its $144B portfolio in Q3 2018.
- Barclays opened 680 new positions and closed 408 in Q3 2018.
- Barclays's portfolio value rose 24% quarter-over-quarter to $144B.
Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.